Tafnext Dosage/Direction for Use

Testing Prior to Initiation of Tenofovir Alafenamide: Prior to initiation of Tenofovir Alafenamide, patients should be tested for HIV-1 infection. Tenofovir Alafenamide alone should not be used in patients with HIV-1 infection (see Precautions).
Prior to or when initiating Tenofovir Alafenamide, and during treatment with Tenofovir Alafenamide on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus (see Precautions).
Recommended Dosage in Adults: The recommended dosage of Tenofovir Alafenamide is 25 mg (one tablet) taken orally once daily with food (see Pharmacology under Actions).
Dosage in Patients with Renal Impairment: No dosage adjustment of Tenofovir Alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 mL per minute, or in patients with end stage renal disease (ESRD; estimated creatinine clearance below 15 mL per minute) who are receiving chronic hemodialysis. On days of hemodialysis, administer Tenofovir Alafenamide after completion of hemodialysis treatment.
Tenofovir Alafenamide is not recommended in patients with ESRD who are not receiving chronic hemodialysis (see Precautions and Pharmacology under Actions).
Dosage in Patients with Hepatic Impairment: No dosage adjustment of Tenofovir Alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir Alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment (see Precautions and Pharmacology under Actions).